-
About ovarian cancer
- What is ovarian cancer?
- Ovarian cancer risk
- Hereditary ovarian cancer
- Symptoms
- Testing
- Treatment
- Your situation
- Coronavirus and ovarian cancer
- A-Z of ovarian cancer
- Clinical trials
- Support for you
- Stories
-
Get involved
- Fundraise for us
- Events and challenges
-
Campaign
- Become a campaigner
-
Campaigning toolkit
- Campaigning on ovarian cancer across the UK
- Email your elected representatives
- Meet with your elected representatives
- Influence your Clinical Commissioning Group (CCG)
- Campaign by raising awareness of ovarian cancer
- Write to your local newspapers
- Take action through craftivism
- Grow our movement
- Top tips and resources for campaigning
- Current campaigns
- Campaigning successes
- APPG on Ovarian Cancer
- Policy
- Raise awareness
- Volunteer
- Leave a gift in your will
- Remember someone special
- Ovarian Cancer Awareness Month
- Become a corporate partner
- Trusts and foundations
- Give more for less
- Make a donation
Sitemap
- News
- Health professionals
-
Research
- Our strategy
-
Our projects
- Developing new treatments for low-grade serous ovarian cancer
- Finding new treatment approaches for drug-resistant ovarian cancer
- Unlocking the power of the immune system
- Translating our knowledge of the DNA damage response into clinical benefits for patients
- Interleukin-6 as a therapeutic target in ovarian clear cell carcinoma
- EDMONd: diet and nutrition for patients with inoperable malignant bowel obstruction
- Circulating tumour DNA as a specific diagnostic biomarker for ovarian cancer
- Personalised therapy in ovarian cancer: targeting FEN1
- GTEOC study
- Targeting microtubules to overcome resistance to chemotherapy drugs
- Palliative chemotherapy to manage symptoms in women with recurrent ovarian cancer
- Our champions
- Our policies
- Apply for funding
- Fund our research
- About us
- Email signup
